

Discover what SomaLogic is up to

AACR 2023
Booth 1618

somalogic



Proteomics has emerged as the next frontier in precision medicine and several innovative proteomics platforms have emerged or are under development that are driving biomarker discovery to the next level. We are using the currently most comprehensive proteomics technology, the SomaScan® platform, which measures 7,000 proteins to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers. Our efforts are especially focused on non-invasive biomarkers in serum, plasma, urine, and exosomes for a broad range of clinically highly relevant and challenging indications. Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will be presented.

Exhibitor Spotlight Theater*

Session Date and Time	Session Title	Presenter
Tuesday, April 18 3:00 - 4:00 PM	Accelerating Precision Medicine of Cancer with SomaScan® Proteomics	Towia Libermann, Ph.D. Associate Professor of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School

Abstract Presentations

Session Date and Time	Session Title	Presenter
Tuesday, April 18 9:00 AM - 12:30 PM	P38.04: The plasma proteome as a cardiovascular disease risk assessment tool in cancer survivors	Jessica Kuzma, Ph.D. Scientist II, Clinical R&D
Tuesday, April 18 1:30 - 5:00 PM	P32.27: Efficient development of prognostic tests for detecting cancer risk using proteomic technology	Yolanda Hagar, Ph.D. Associate Director, Bioinformatics

* This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research; (AACR).